Gatza Lab Publications

  1. Liu J, Zhang C,  Zhao Y, Yue X, Huang S, Chen J, Wu H, Tomsky K, Teutle M, Khella CA, Gatza ML, Xia D, Gao J; Haffty BG, Hu W, Feng Z. (2017). Parkin targets HIF-1α for ubiquitination and degradation to inhibit tumor progression. Nature Communications. Online 28 Nov 2017  PDF
  2. Brighton HE, Angus SP, Bo T, Roques J, Tagliatela AC, Darr DB, Karagoz K, Sciaky N, Gatza ML, Sharpless NE, Johnson GL, and Bear JE (2017). Intravital imaging of melanoma in combination with molecular analysis reveals key changes in stromal ECM and tumor reprogramming in response to MEKi. Cancer Research. Online 27 Nov 2017 PDF
  3. Lu K, Alcivar AL, Ma J, Foo TK, Zywea S, Huo Y, Kensler TW, Gatza ML and Xia B (2017). NRF2 induction supporting breast cancer cell survival is enabled by oxidative stress-induced DPP3-KEAP1 interaction. Cancer Research. Online April 17, 2017. PDF
  4. Mehta GA, Parker JS, Silva GO, Hoadley KA, Perou CM, Gatza ML. (2017). Amplification of SOX4 promotes PI3K/Akt signaling in human breast cancer. Breast Cancer Research and Treatment. 162(3):439-450. PDF
  5. Mertins P, Mani DR, Ruggles KV, Gillette MA, Clauser KR, Wang P, Wang X, Qiao JW, Cao S, Petralia F, Kawaler E, Mundt F, Krug K, Tu Z, Lei JT, Gatza ML, Wilkerson M, Perou CM, Yellapantula V, Huang KL, Lin C, McLellan MD, Yan P, Davies SR, Townsend RR, Skates SJ, Wang J, Zhang B, Kinsinger CR, Mesri M, Rodriguez H, Ding L, Paulovich AG, Fenyö D, Ellis MJ, Carr SA; NCI CPTAC. (2016). Proteogenomics connects somatic mutations to signaling in breast cancer. Nature. 534(7605):55-62. PDF
  6. Gatza ML and Carey LA (2016). Another breast cancer entity confirmed: Genomics of invasive lobular breast cancer. Journal of Clinical Oncology. 34(16):1838-9. PDF
  7. Ciriello G*, Gatza ML*, et al. (2015). Comprehensive molecular characterization of invasive lobular breast tumors. Cell. 163(2):506-19. *Authors contributed equally PDF
  8. Silva GO, He X, Parker JS, Gatza ML, et al.  (2015). Across Species DNA Copy Number Analyses Identifies Subtype-Specific Drivers of Breast Cancer Development. Breast Cancer Research and Treatment. 152(2):347-356. PDF
  9. Young CD, Zimmerman LJ, Hoshino D, Formisano L, Hanker AB, Gatza ML, et al.  (2015). Activating PIK3CA mutations induce an EGFR/ERK paracrine signaling axis in basal-like breast cancer. Molecular and Cellular Proteomics. 14(7):1959-76. PDF
  10. Tian H, Liu J, Chen J, Gatza ML, Blobe GC (2015). Fibulin-3 is a Novel TGF-β pathway Inhibitor in the Breast Cancer Microenvironment. Oncogene. Online March 2015. PDF
  11. Gatza ML, et al. (2014). An integrated genomics approach identifies drivers of proliferation in luminal subtype human breast cancer. Nature Genetics. 46(10): 1051-1059. PDF
  12. Shats I, Gatza ML, et al. (2013). Cooperation between E2F1 and FOXO transcription factors provides a mechanism for control of E2F1-mediated transcription by survival signaling. Cancer Research.  73(19):6056-67. PDF
  13. Liu B, Shats I, Angus S, Gatza ML, Nevins JR (2013). Interaction of E2F7 with E2F1 and C-terminal binding protein (CtBP) provides a mechanism for E2F7-dependent transcription repression. Journal of Biological Chemistry. 288(34):245281-24589. PDF
  14. Mythreye K, Knelson EH, Gatza CE, Gatza ML, Blobe GC. (2013). TβRIII/β-arrestin2 suppresses epithelial derived cancer progression by regulating integrin α5β1 trafficking, function, and localization. Oncogene. 32 (11): 1416–1427. PDF
  15. Gatza ML, et al. (2011). Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes. Breast Cancer Research13(3):R62. (Highly Accessed) PDF
  16. Chang JT, Gatza ML, et al. (2011). SIGNATURE: A workbench for gene expression signature analysis. BMC Bioinformatics. 12(1):443. (Highly Accessed). PDF
  17. Gatza CE, Holtzhausen A, Kirkbride KC, Morton A, Gatza ML, et al. (2011). The Type III TGF-β Receptor enhances colon cancer cell migration and anchorage independent growth. Neoplasia. 13(8): 758-770. PDF
  18. Shats I, Gatza ML, et al. (2011). Using a stem cell-based signature to guide therapeutic selection in cancer. Cancer Research. 71(5): 1772-1780. PDF

  19. Gatza ML, et al. (2010).  A pathway based classification of human breast cancer. Proc. Nat’l. Acad. Sci. 107(15):6994-6999. PDF
  20. Andrechek ER, Cardiff RD, Chang JT, Gatza ML, et al. (2009). Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential. Proc. Nat’l Acad. Sci. 106 (38):16387-16392. PDF
  21. Mori S, Chang JT, Andrecheck ER, Matsumura N, Baba T, Yao G, Kim JW, Gatza M, et al. (2009).  Anchorage-independent cell growth signature identified tumors with metastatic potential. Oncogene. 28 (31): 2796-2805.  PDF
  22. Chang JT, Carvalho C, Mori S, Bild AH, Gatza ML, et al (2009).  A Genomic strategy to elucidate modules of oncogenic pathway signaling networks. Molecular Cell. 34(1): 104-114. PDF
  23. Gatza ML, et al. (2007). Ubiquitination of HTLV-I Tax mediates TSS complex disruption and Tax nuclear export in response to DNA damage. Retrovirology. 4: 95. PDF
  24. Gatza ML and Marriott SJ. (2006).Genotoxic stress and cellular stress alter the subcellular distribution of human T cell leukemia virus type 1 Tax through a CRM1 dependent mechanism.  Journal of Virology.  80 (13): 6657- 6668. PDF
  25. Gatza ML, et al. (2005). Impact of transforming viruses on cellular mutagenesis, genome stability, and cellular transformation. Environmental and Molecular Mutagenesis. 45 (2-3): 304-325. PDF
  26. Gatza ML, et al. (2003) Cellular Transformation by the HTLV-Tax protein, a jack-of-all-trades. Oncogene. 22 (33):5141-5149. PDF





precision medicine at Rutgers Cancer Institute







Donate Now








Proud member of
Big Ten Cancer Research Consortium



Rutgers Health